Semaglutide users may face hidden surgery risk, ultrasound study finds

NCT ID NCT06263595

Completed Knowledge-focused Sponsor: University of Calgary Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study used ultrasound to measure stomach contents in 94 patients before surgery, comparing those on semaglutide (a GLP-1 drug for diabetes/weight loss) to those not taking it. The goal was to see if semaglutide increases the risk of a 'full stomach' despite following fasting rules, which could lead to dangerous aspiration during anesthesia. Researchers hope the findings will help create safer fasting guidelines for these patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide
What this could lead to: If successful, this could lead to better fasting guidelines for patients on semaglutide before surgery, reducing the risk of aspiration pneumonia.
What could go wrong: This is a small, completed observational study (94 participants) that only measures stomach volume, not actual aspiration events. Results may not apply to all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY ASPIRATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aspiration pneumonia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY ASPIRATION

Contacts and locations

Locations

South Health Campus

Calgary, Alberta, T3M 1M4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.